{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:12:07Z","timestamp":1760242327299,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The aim of this study was to characterize the treatment response and serious adverse events of ledipasvir plus sofosbuvir therapies in Japanese patients infected with hepatitis C virus (HCV) genotype 1 (GT1). This retrospective study analyzed 240 Japanese HCV GT1 patients treated for 12 weeks with 90 mg of ledipasvir plus 400 mg of sofosbuvir daily. Sustained virological response at 12 weeks post-treatment (SVR12) was achieved in 236 of 240 (98.3%) patients. Among treatment-na\u00efve patients, SVR12 was achieved in 136 of 138 (98.6%) patients, and among treatment-experienced patients, SVR12 was achieved in 100 of 102 (98.0%) patients. In patients previously treated with peginterferon plus ribavirin with various HCV NS3\/4A inhibitors, 100% SVR rates (25\/25) were achieved. Two relapsers had HCV NS5A resistance-associated variants (RAVs), but no HCV NS5B-S282 was observed after they relapsed. We experienced two patients with cardiac events during treatment. In conclusion, combination of ledipasvir plus sofosbuvir for 12 weeks is a potential therapy for HCV GT1 patients. Caution is needed for HCV NS5A RAVs, which were selected by HCV NS5A inhibitors and cardiac adverse events.<\/jats:p>","DOI":"10.3390\/ijms18050906","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T13:21:12Z","timestamp":1493126472000},"page":"906","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3\/4A Inhibitors"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9565-4669","authenticated-orcid":false,"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Yasui","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Ooka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadahisa","family":"Ogasawara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhiro","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Haga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reina","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Nakamoto","sequence":"additional","affiliation":[{"name":"Department of Molecular Virology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Tawada","sequence":"additional","affiliation":[{"name":"Safety and Health Organization, Chiba University, 1-33 Yayoicho, Inage-ku, Chiba 263-8522, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Imazeki","sequence":"additional","affiliation":[{"name":"Safety and Health Organization, Chiba University, 1-33 Yayoicho, Inage-ku, Chiba 263-8522, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-2818","authenticated-orcid":false,"given":"Naoya","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Yokosuka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,4,25]]},"reference":[{"key":"ref_1","unstructured":"(2017, March 28). Survival Statistics of Japanese Association of Clinical Cancer Centers. Cancer Survival Rates at Japanese Association of Clinical Cancer Centers. Available online: https:\/\/kapweb.chiba-cancer-registry.org\/?lang=en."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00535-014-0973-8","article-title":"Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: A large retrospective multicenter cohort study","volume":"50","author":"Tateishi","year":"2015","journal-title":"J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/liv.13071","article-title":"Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: A propensity score analysis","volume":"36","author":"Tada","year":"2016","journal-title":"Liver Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00535-009-0131-x","article-title":"Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus","volume":"45","author":"Noda","year":"2010","journal-title":"J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12072-012-9342-y","article-title":"APASL consensus statements and management algorithms for hepatitis C virus infection","volume":"6","author":"Omata","year":"2012","journal-title":"Hepatol. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1111\/j.1365-2893.2011.01512.x","article-title":"Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up","volume":"19","author":"Maruoka","year":"2012","journal-title":"J. Viral Hepat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/hep.24724","article-title":"Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders","volume":"55","author":"Chayama","year":"2012","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wu, S., Kanda, T., Nakamoto, S., Jiang, X., Miyamura, T., Nakatani, S.M., Ono, S.K., Takahashi-Nakaguchi, A., Gonoi, T., and Yokosuka, O. (2013). Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: Ultra-deep sequencing analysis of HCV NS5B genotype-specific region. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0073615"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s00535-016-1225-x","article-title":"Efficacy of daclatasvir\/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1","volume":"52","author":"Iio","year":"2017","journal-title":"J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","article-title":"Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options","volume":"58","author":"Suzuki","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"418","DOI":"10.7150\/ijms.15519","article-title":"Daclatasvir plus Asunaprevir treatment for real-world HCV genotype 1-infected patients in Japan","volume":"13","author":"Kanda","year":"2016","journal-title":"Int. J. Med. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.27826","article-title":"Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis","volume":"62","author":"Reddy","year":"2015","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: An open-label, randomised, phase 3 trial","volume":"15","author":"Mizokami","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3390\/v4081264","article-title":"Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin","volume":"4","author":"Miyamura","year":"2012","journal-title":"Viruses"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s12072-012-9349-4","article-title":"Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1","volume":"7","author":"Miyauchi","year":"2013","journal-title":"Hepatol. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12072-015-9624-2","article-title":"HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b","volume":"9","author":"Hirotsu","year":"2015","journal-title":"Hepatol. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/jvh.12549","article-title":"Resistance analyses of Japanese hepatitis C-Infected patients receiving sofosbuvir or ledipasvir\/sofosbuvir containing regimens in phase 3 studies","volume":"23","author":"Mizokami","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ogawa, E., Furusyo, N., Nomura, H., Dohmen, K., Higashi, N., Takahashi, K., Kawano, A., Azuma, K., Satoh, T., and Nakamuta, M. (2016). NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. J. Gastroenterol.","DOI":"10.1007\/s00535-016-1290-1"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Iio, E., Shimada, N., Takaguchi, K., Senoh, T., Eguchi, Y., Atsukawa, M., Tsubota, A., Abe, H., Kato, K., and Kusakabe, A. (2017). Clinical evaluation of sofosbuvir\/ledipasvir in chronic hepatitis C genotype 1 with and without prior daclatasvir\/asnaprevir therapy. Hepatol. Res.","DOI":"10.1111\/hepr.12898"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Akuta, N., Sezaki, H., Suzuki, F., Fujiyama, S., Kawamura, Y., Hosaka, T., Kobayashi, M., Kobayashi, M., Saitoh, S., and Suzuki, Y. (2017). Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. J. Med. Virol.","DOI":"10.1002\/jmv.24767"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"AASLD\/IDSA HCV Guidance Panel (2015). Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology, 62, 932\u2013954.","DOI":"10.1002\/hep.27950"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. Electronic address: Easloffice@easloffice.eu. (2017). EASL Recommendations on Treatment of Hepatitis C 2016. J. Hepatol., 66, 153\u2013194.","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"ref_28","first-page":"1","article-title":"Treatment of hepatitis C virus infection: Updated Swedish Guidelines 2016","volume":"15","author":"Lagging","year":"2017","journal-title":"Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.3748\/wjg.v20.i11.2902","article-title":"Hepatitis C virus NS5A inhibitors and drug resistance mutations","volume":"20","author":"Nakamoto","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","article-title":"Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: A randomised, double-blind, phase 2 trial (SIRIUS)","volume":"15","author":"Bronowicki","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_32","unstructured":"European Association of the Study of the Liver (2012). 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int., 32, 2\u20138."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"European Association for Study of Liver (2014). EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J. Hepatol., 60, 392\u2013420.","DOI":"10.1016\/j.jhep.2013.11.003"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMc1505967","article-title":"Bradyarrhythmias Associated with Sofosbuvir Treatment","volume":"373","author":"Fontaine","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1053\/j.gastro.2015.07.051","article-title":"Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge","volume":"149","author":"Renet","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"44820","DOI":"10.1038\/srep44820","article-title":"Cardiac drug-drug interaction between HCV-NS5B pronucleotide inhibitors and amiodarone is determined by their specific diastereochemistry","volume":"7","author":"Lagrutta","year":"2017","journal-title":"Sci. Rep."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/5\/906\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:33:45Z","timestamp":1760207625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/5\/906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,25]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5]]}},"alternative-id":["ijms18050906"],"URL":"https:\/\/doi.org\/10.3390\/ijms18050906","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2017,4,25]]}}}